Postmenopausal hormone use in women with acute coronary syndromes

Journal of Women's Health

Volumn 13, Issue 8, 2004, Pages 863-870

  Parsons, Elizabeth ^a   Newby, L Kristin ^b   Bhapkar, Manjushri V ^b   Alexander, Karen P ^b   White, Harvey D ^c   Shah, Svati H ^b   Bushnell, Cheryl D ^b   Califf, Robert M ^b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c GREEN LANE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; PIPERAZINE ESTRONE SULFATE; SIBRAFIBAN;

ADULT; ANGINA PECTORIS; ARTICLE; ASIA; AUSTRALIA; CANADA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; EASTERN EUROPE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NEW ZEALAND; OUTCOMES RESEARCH; PATIENT CODING; POSTMENOPAUSE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REVASCULARIZATION; RISK BENEFIT ANALYSIS; SMOKING; SOUTH AND CENTRAL AMERICA; STATISTICAL ANALYSIS; STROKE; UNITED STATES; WESTERN EUROPE;

EID: 9144248403     PISSN: 15409996     EISSN: None     Source Type: Journal    
DOI: 10.1089/jwh.2004.13.863     Document Type: Article

References (36)

1. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801.
2. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47.
3. Sidney S, Petitti DR, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Arch Intern Med 1994;154:1333.
4. Sullivan JM, Vander Zwaag R, Hughes JP, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557.
5. Newton KM, LaCroix AZ, McKnight B, et al. Estrogen replacement therapy and prognosis after first myocardial infarction. Am J Epidemiol 1997;145:269.
6. O'Brien JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28:1111.
7. Sullivan JM, El-Zewky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997;79:847.
8. Hulley S, Grady D, Bush T, et al., for Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280:605.
9. Grady D, Herrington D, Bittner V, et al., for the HERS Research Group. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA 2002;288:49.
10. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: A randomized controlled trial. JAMA 2002;288:2432.
11. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321.
12. Herrington DM, Reboussin DM, Brosnihan KB, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522.
13. Schulman SP, Thiemann DR, Ouyang P, et. al. Effects of acute hormonal therapy on recurrent ischemia in postmenopausal women with unstable angina. J Am Coll Cardiol 2002;39:231.
14. Alexander KP, Newby LK, Hellkamp AS, et al. Initiation of hormone replacement therapy after acute myocardial infarction is associated with more unstable angina during follow-up. J Am Coll Cardiol 2001;38:1.
15. Viscoli CM, Lawrence MB, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke (Women's Estrogen for Stroke Trial). N Engl J Med 2001; 345:1243.
16. Finucane F, Madans JH, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users: Results from a national cohort. Arch Intern Med 1993;153:73.
17. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: A prospective study. Br Med J 1988;297:519.
18. Sourander L, Rajala T, Raiha I, et al. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998;352:1965.
19. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75.
20. Schairer C, Adami HO, Hoover R, et al. Cause-specific mortality in women receiving hormone replacement therapy. Epidemiology 1997;8:59.
21. The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomized trial. Lancet 2000;355:337.
22. The 2nd SYMPHONY Investigators. A randomized comparison of sibrafiban plus aspirin, aspirin alone, and sibrafiban alone for prevention of ischemic events after acute coronary syndromes. Circulation 2001; 103:1727.
23. Newby LK, for the SYMPHONY Steering Committee. Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute coronary syndromes (SYMPHONY) trial. Am Heart J 1999;138:210.
24. Newby LK, Bhapkar MV, White HD, et al., for the SYMPHONY and 2nd SYMPHONY Investigators. Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. Eur Heart J 2003; 24:172.
25. Finley C, Gregg EW, Solomon LJ, Gay E. Disparities in hormone replacement therapy use by socioeconomic status in a primary care population. J Community Health 2001;26:39.
26. Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate alone or in combination, in women with postmenopausal osteoporosis. Am J Med 1998;104:219.
27. Amonkar MM, Mody R. Developing profiles of postmenopausal women being prescribed estrogen therapy to prevent osteoporosis. J Community Health 2002;27:335
28. Strinic T, Bukovic D, Karelovic D, et al. Socio-demographic characteristics of postmenopausal estrogen users. Collegium Anthropologicum 2002;26:245.
29. Hundrup YA, Thoning H, Obel EB, Rasmussen NK, Philip J. Lifestyle factors and choice of hormone replacement therapy among Danish nurses. Scand J Public Health 2002;30:47.
30. Progetto Menopausa Italia Study Group. General and medical factors associated with hormone replacement therapy among women attending menopause clinics in Italy. Menopause 2001;8:290.
31. Keating NL, Cleary PD, Rossi AS, Zaslavsky AM, Ayanian JZ. Use of hormone replacement therapy by postmenopausal women in the United States. Ann Intern Med 1999;130:545.
32. Levy BT, Ritchie JM, Smith E, Gray T, Zhang W. Physician specialty is significantly associated with hormone replacement therapy use. Obstet Gynecol 2003;101:114.
33. Stafford RS, Saglam D, Causino N, Blumenthal D. Low rates of hormone replacement in visits to United States primary care physicians. Am J Obstet Gynecol 1997;177:381.
34. Handa VL, Landerman R, Hanlon JT, Harris T, Cohen HJ. Do older women use estrogen replacement? Data from the Duke Established Populations for Epidemiologic Studies of the Elderly (EPESE). J Am Geriatr Soc 1996;44:1.
35. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative Randomized Controlled Trial. JAMA 2004;291:1701.
36. Cherry N, Gilmour K, Hannaford P, et al., and the ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet 2002;360:2001.